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Much has been written about the seemingly less formal, more agile biotechnology industry and its
extensive interactions with academia and startups, as well as its distinct scientific, manufacturing and
regulatory profile.  Employing a data base encompassing all 96 biologics and 212 small molecules
newly launched in the U.S. between 1998Q1 and 2008Q4, we compare their downstream clinical and
commercial characteristics -- therapeutic class concentration, launch delays following approval, Orphan
Drug and priority review status, supplemental indications, black box warning and safety record, and
pricing and revenue growth during the product life cycle.  We conclude that the market dynamics of
biologics differ substantially from those of small molecules, although therapeutic class composition
plays a major role.
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I.  INTRODUCTION AND BACKGROUND 
The  biotechnology  therapeutic  industry  is  relatively  young,  tracing  its 
creation  to  science  breakthroughs  in  the  1970s.    Cetus  was  founded  in  1971, 
Genentech  in  1976,  and  Genzyme  in  1981.      The  first  U.S.  sales  of  a  major 
recombinant therapeutic—human insulin—occurred in 1982.  A decade later in 
1992 Amgen became the first biotech Fortune 500 company, driven by the sales 
of Epogen (epoietin alfa).  A decade later, just after the millennium, the human 
genome was sequenced leading to an explosion of new companies pursuing novel 
therapeutic targets. Today, in the midst of an economic crisis, the biotechnology 
industry  is  retrenching  while  simultaneously  moving  forward  hundreds  of 
candidate therapeutic products.   
The  biotechnology  industry  has always  been  a  mix of genetic research 
techniques and the resultant biologic products.  Therefore  defining the industry is 
challenging, for the techniques can be used to produce products not thought of as 
biologic.    Biologic  products  span  industrial,  agricultural,  food  processing  and 
healthcare markets.  In addition, commercial evolution, particularly over the past 
decade, has further blurred the biotechnology identity as large biopharmaceutical 
companies formerly focused entirely on small molecules now develop and market 
both biologic and small molecule drugs, while small ―biotech‖ companies often 
use genetic research techniques to create small molecule therapies.  
We focus here on biologic human therapeutic products.  These medicines 
are  produced  by  living  organisms  and  then  isolated  by  various  separation 
technologies.  Because of their size and complexity, particularly with regard to 
their folding and chirality-their ‗handedness‘, these medicines are not made by 
chemical  synthesis  as  are  small  molecules.    Sometimes  they  are  made  from 
extracts of animal blood or tissues.  Some blood products to enhance clotting for 
hemophiliacs, or avoid clotting  for cardiac patients, are  made this  way as are 
some forms of insulin for diabetics.  Vaccines are still mostly made by inoculating 
chicken eggs and then isolating the antigens after a period of time.  This is one 
reason  rapidly  expanding  production  for  pandemics  has  proven  difficult.      In 
many cases today, however, biologics are made by animal, yeast or bacteria cells 
that have had a gene, often a human gene, inserted into them.  Using that genetic 
blueprint, the cells then use  all their other DNA, RNA and protein producing 
mechanisms  to  make  the  desired  product,  along  with  all  the  other  structures, 
products and wastes that cells create to live.  So not only are biologic therapeutics 
(biologics) themselves larger and more complex than traditional small molecule 
medicines  like  aspirin,  their  production  methods  are  also  more  complex  and 
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orally  because the patient‘s digestive track would deconstruct them  as a  large 
protein for food.  Thus, biologics must often be injected or infused rather than 
swallowed.  As a result, biologics are often administered by health care providers 
in  physician  offices  or  clinics,  unlike  self-administered  tablets  and  capsules.  
Moreover, many biologics are covered by a medical rather than pharmaceutical 
benefit in health insurance plans. 
For all these reasons of innate biology, production and dosing approach, 
biologics  often  differ  from  small  molecule  medicines  in  their  product 
development, regulatory approval, distribution and commercial paths.  Thus while 
having  the  same  medical  goals-to  treat  disease,  small  molecule  and  biologic 
therapeutics differ substantially in ways that might affect innovation, safety, costs, 
clinical adoption, patient access and pricing.  Biologics are now about a third of 
the  medicines  approved.    Understanding  whether  their  biological  differences 
translate  into  commercial  and  economic  differences  is  therefore  important  for 
understanding  health  care  economics,  effective  innovation  incentives  and 
anticipated public health improvements. 
Much  has  been  written  about  the  seemingly  less  formal,  more  agile 
biotech industry and about its extensive interfaces among academia and startups.  
Recently a literature has also developed that compares the costs of developing 
biologics vs. small molecules.  For example, see Berndt, et al. (2009), Calfee and 
Dupre (2006), and DiMasi and Grabowski (2007). Literature also addresses the 
time  and  cost  differences  across  therapeutic  classes  in  bringing  new 
biopharmaceuticals  to  market.  Among  articles  addressing  this  issue,  see 
Abrantes-Metz et al. (2005, 2008), Adams and Brantner (2006, 2009), Danzon, et 
al.  (2005),  DiMasi  et  al.  (2004),  and  DiMasi  et  al.  (2003).  This  literature 
demonstrates that biologics and small molecules have reasonably similar costs to 
bring to market, though success rates vary at different development phases. 
Within the recent past much attention has also been given to the potential 
for generic or biosimilar pathways  for biologics that could  in principle  mimic 
what the Hatch-Waxman 1984 legislation did for small molecules.  On this, see, 
for example, Cacciatore et al. (2008), Grabowski (2008), Grabowski et al. (2006), 
Grabowski and Kyle (2008), Grabowski et al. (2007), Hollingshead and Jacoby 
(2009),  Kotlikoff  (2008),  Mishra  (2009)  and  U.S.  Federal  Trade  Commission 
(2009).  With passage of health care reform in 2010, a regulatory pathway for 
biosimilar products was created, and biologics were granted a twelve year data 
exclusivity, longer than the five years accorded small molecules.    
Over  the  last  year  the  pace  of  merger  announcements  has  increased, 
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small molecule pharmaceutical companies, such as those between Genentech and 
Roche, Schering Plough and Merck, and Wyeth and Pfizer. These combinations 
raise  issues  concerning  possible  new  directions  for  traditional  pharmaceutical 
companies.  Will these mergers result in the synergies and amplified success their 
originators expect or will they result in mismatched organizations such as  that 
experienced  by  the  integrated  financial  service  companies  and  life  science 
conglomerates in the late 1990s?   
Although we build on these various literatures and industry experiences, 
our  focus  here  shifts  downstream  –  subsequent  to  the  FDA  approving  a  new 
therapeutic.    At  the  level  of  the  individual  product,  the  difference  between 
biologic and small molecule drugs remains sharp as scientific characterization, 
manufacturing process and regulatory reviews have tended to remain substantially 
distinct.       It  is  at  this  level  of  individual  products,  rather  than  aggregate 
organizations,  that  we  focus  our  attention  and  examine  how  the  clinical  and 
market experiences differ depending on whether thet therapeutic is a biologic or a 
small molecule.  
We begin our analysis by examining several potential clinical distinctions 
between  biologics  and  small  molecules  that  may  have  substantial  commercial 
implications.  Are the diseases and conditions for which biologics are approved 
different from those for small molecules?  Is there a sense in which biologics 
embody more significant medical innovation than do small molecules?  Are there 
differences  in  safety  profiles,  and  rates  of  product  exit?    Since  biologics  are 
largely  infused  or  injected,  whereas  small  molecules  are  most  commonly 
delivered in oral tablet/capsule form – are there differences in physician specialty 
types who prescribe biologics vs. small molecules?   
Having characterized clinical issues such as therapeutic area, innovation, 
provider  and  safety  differences  and  similarities  among  biologics  and  small 
molecules,  we  then  go  on  to  consider  commercial  market  issues.    Over  their 
product life cycles, do patterns of revenue growth since  initial product launch 
differ?  Do small molecule revenues on average grow more rapidly and to greater 
levels than do biologics?  In the late stages of the product life cycle shortly before 
loss  of  patent  protection,  do  biologic  and  small  molecule  sales  revenues  and 
clinical/payer value (as reflected in real price growth) continue to increase, or do 
they tail off? 
We examine these various issues empirically, employing a data base that 
encompasses all new biologics and small molecules launched in the U.S. from 
1998Q1 though the end of 2008Q4 – an 11 year time frame.  CHARACTERIZING  MARKETS  FOR  BIOPHARMACEUTICAL  INNOVATIONS: 
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The outline of our article is as follows.  We begin with a definition of what 
we consider a biologic vs. a small molecule.  We next describe the construction of 
a unique, complete, curated and annotated data set derived from a wide variety of 
sources that include all 308  new  molecular entities (―NMEs‖)  launched  in the 
United  States  over  the  eleven  year  period,  and  then  briefly  outline  statistical 
methods we employ.  Next we present results of analyses concerning similarities 
and differences  in  biologic and small  molecule  product characteristics such as 
therapeutic  area  prevalence,  along  with  various  measures  of  innovation  and 
safety.    We  follow  up  this  more  clinical  discussion  with  an  examination  of 
comparative commercial experiences, such as real dollar sales, growth and pricing 
over the product life cycle.  We then discuss our findings in a broader context, 
and suggest issues meriting future research.  Finally, we summarize findings and 
identify limitations of the data and analyses. 
II.  DATA SOURCES AND METHODS 
To examine the differences and similarities between biologics and small 
molecule  products  we  constructed  the  TABITHA  (Trusheim,  Aitken,  Berndt 
Innovative Therapeutics Historical Archive) database which includes information 
from the IMS Health MIDAS database, the FDA, the World Health Organization 
and  the  U.S.  Bureau  of  Economic  Analysis  for  all  new  molecular  entity 
therapeutic products launched in the U.S. from 1998Q1 through 2008Q4.
1  The 
data  set  was  hand  curated  and  subject  to  multiple  cross  checking  and  data 
integrity  checks  as  described  bel ow.    Error!  Reference  source  not  found. 
illustrates the data sources as well as the data curation and annotation methods we 
employed. 
A.  DEFINITION:  WHAT IS A BIOLOGIC? 
Before  describing  the  data  sources  and  curation  steps,  we  believe  it  is 
important to be clear about distinguishing between biologic and small molecule 
medicines.    In  the  introduction  we  provided  a  general  sense  of  what  makes 
biologics unique and how they differ from traditional, small molecule medicines.  
For the purposes of this paper, we adopt the specific technical biologic definition 
as developed and implemented by IMS Health in its IMS MIDAS information 
resource.  The definition is intended to yield a set of molecules that are relevant to 
                                                 
1  Note  that  our inclusion and  exclusion  criteria  involve  launch  date, not  FDA  approval  date.  
Launch date is determined by identifying the first month in which IMS Health observes 
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market analysis.  For a molecule to be defined as a biologic, it must possess the 
following characteristics: 
   Molecular structure:  Specific macromolecules included in the definition are 
proteins, nucleic acids and carbohydrates.  Current conventions can refer to a 
collection  of  molecules  as  a  single  entity  (e.g.,  antisera).    Only  if  all  the 
components in such a collection are biologic molecules will this collective 
entity be deemed a biologic. 
  Molecular identification:  Biologic molecules must be clearly identified.  Any 
―molecule‖  where  the  molecule  name  is  descriptive  and  the  actual 
composition of the molecule is not identified (e.g., vegetable extract) is not 
classified as a biologic. 
  Active substance:  Biologic molecules must be, or are intended to be, clearly 
defined active therapeutic ingredients embodied within a product. 
  Regulatory:  Biologic molecules must have undergone (or be undergoing) a 
regulatory human clinical trial program under the auspices of a national or 
regional regulatory authority. 
Those therapeutics which did not meet these criteria remain classified as 
small molecule therapeutics. 
B.  CORE DATA SET:  SALES AND UNIT VOLUMES 
We extracted U.S. sales and unit volume data for all NMEs and  novel 
biologics  launched  from 1998-2008, inclusively, from the global IMS MIDAS 
database.  Generic sales and volumes are not included in this data set, since none 
of the products approved since 1998 experienced loss of patent protection by the 
end of 2008. 
The IMS MIDAS database provides therapeutic product U.S. market sales 
at the ex-manufacturer level, as well as standard unit volume data.  We calculate 
price as unit value (sales revenues/standard units).  Sales revenue values are based 
on wholesaler invoice data, and therefore include prompt payment discounts and 
chargebacks, but do not include rebates given to non-providers (non-mail order 
PBMs, third party payers, HMOs, etc.).   CHARACTERIZING  MARKETS  FOR  BIOPHARMACEUTICAL  INNOVATIONS: 
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Figure 1:  Data Sourcing, Annotation and Curation Process 
 CHARACTERIZING  MARKETS  FOR  BIOPHARMACEUTICAL  INNOVATIONS: 
DO BIOLOGICS DIFFER FROM SMALL MOLECULES? 
Page 7    NBER Working Paper w16014 
C.  PRODUCT SALES AND VOLUME DATA CURATION 
The core data set was hand curated for data quality and satisfaction of all 
selection  criteria  through  a  multistage  process  of  selection  validation,  missing 
data  screening,  derived  data  creation  (such  as  GDP  deflated  constant  dollar 
transformation  and  relative  launch  date  alignment),  and  minimal  threshold 
trimming. 
In  terms  of  selection  validation,  we  initially  identified  444  named 
therapeutic products as approved or commercially introduced branded products in 
the  U.S.  during,  or  near  the  January  1998  –  December  2008 time  period.    A 
product was determined as qualifying for inclusion if it met the following primary 
criteria: 
1.  The product was approved by the FDA or had its first full quarter of 
sales between January 1, 1998 and December 31, 2008; 
AND EITHER: 
2A.    The  FDA  Center  for  Drug  Evaluation  and  Research  (CDER) 
classified  the  product‘s  Chemical  Type  as  ‗1  New  Molecular  Entity‘  OR  the 
product  was  a  new  formulation  or  packaging  form  of  an  NME  originally 
appearing in the qualified period; 
OR 
2B.  The  FDA  Center  for  Biologics  Evaluation  and  Research  (CBER) 
approved  the  product‘s  original  (not  supplemental)  Biological  License 
Application. 
Of  those  444  possible  new  products,  upon  further  examination  we 
identified  110  products  as  new  formulations,  new  manufacturers  of  previous 
products, branded generic introductions, or outside the date range.  We removed 
these 110 products from the analysis. 
We  then  identified  26  products  that  were  formulation  or  packaging 
variations by the original manufacturers of the qualified products.  Although we 
do not consider these as new products, their sales and volumes were added to 
those of the originally qualified product to yield total molecule-specific sales and 
volume data. 
The 308 remaining distinct new products were included in the analysis for 
purposes of product counts.  CHARACTERIZING  MARKETS  FOR  BIOPHARMACEUTICAL  INNOVATIONS: 
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Derived Data Creation Part 1:  To adjust for general inflation, sales data 
for  each  product  were  transformed  using  the  Bureau  of  Economic  Analysis‘ 
quarterly GDP Price Deflator data, with 2005 as the base year.  Monthly GDP 
deflators were linearly interpolated from quarterly values and were then applied to 
the monthly sales data. 
Relative Launch Date Alignment:  The monthly core sales and volume 
data for each product were aligned on the basis of the first month in which sales 
and  volume  were  observed  for  that  product.    Several  products  had  an  initial 
shortened launch followed by a period of low or zero sales, and then a second 
sustained launch thereafter.  The BiogenIdec product Tysabri is an example of 
such a product which was launched, halted and re-launched after a monitoring 
system  was  instituted  for  surveillance  of  a  particularly  concerning  adverse 
reaction.  In such cases, after confirming source data integrity, the initial launch 
was ignored and the data were aligned to the first month of the second sustained 
launch.  Data were aggregated from monthly to quarterly sales and standard unit 
volumes.  Final quarters with less than three full months of data were truncated 
from the data set. 
Missing Data Screening:  IMS audits generally  cover 99% of the U.S. 
market, although this varies on very low volume products, and on those with very 
specific distribution patterns.  To avoid inappropriate conclusions, some of these 
products, particularly products from Genzyme, were excluded from the growth 
rate and pricing analysis, but were included in analyses based on product counts.  
In addition, products with approval dates in the period but no recorded sales or 
intermittent sales or other factors resulting in zero or missing sales were excluded 
from the growth rate analyses. 
Derived Data Creation Part 2 -- Sales, Volume and Pricing Growth Rates:  
Rolling annual growth rates for sales and standard unit volumes were calculated 
for each quarter compared to the prior year‘s same quarter, to facilitate year-over-
year same quarterly growth computations.  Therefore the first quarter for growth 
rate data is the fifth quarter from launch. Prices were calculated for each product 
by dividing sales by standard unit volumes.  Price growth was then calculated 
using the same methodology as that used for sales and volumes.  Some products 
possessed less than the minimal five quarters of data required to enter the growth 
rate analysis. 
Minimal Threshold Trimming:  To avoid misleading results due to erratic 
quarterly growth rates caused by small or seasonal products, minimal threshold 
rules were implemented based on absolute levels and data continuity.   Several 
minor products with sales under $50,000 (nominal) per month were deleted from CHARACTERIZING  MARKETS  FOR  BIOPHARMACEUTICAL  INNOVATIONS: 
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the analysis.  In addition, products that exited the US market (sales and volume 
data ceased prior to 12/31/2008) were examined for clear market cessation.  Any 
sales  and  volumes  after  an  initial  quarterly  sales  drop  of  90%  or  more  were 
subsequently trimmed from the data set as were those quarters, and subsequent 
quarters,  with  sales  less  than  $150,000  (nominal).  In  addition  two  seasonal 
products with alternating quarters of large and zero sales were trimmed from the 
growth rate and pricing analysis data. 
D.  ANNOTATION WITH PRODUCT REFERENCE DATA 
In addition to the core data set consisting of each product‘s sales, volume 
and price data, each product was further annotated with a broad set of metadata 
regarding its product form, therapeutic class, specialist or primary care physician 
status, FDA status, FDA review process and number of supplemental approvals.  
Biologic Classification:  As discussed above, each product was annotated 
as being either a biologic or a non-biologic product.  For convenience and ease of 
reading, hereafter we refer to non-biologic products as small molecule products 
regardless of which FDA office approved them. 
ATC assignment:  IMS Health assigns  each drug to a therapeutic class 
according to the World Health Organization‘s Anatomical Therapeutic Chemical 
classification  system  (ATC).
2    The ATC system  allocates  drugs into different 
groups according to the organ or system on which they act and  on the basis of 
their chemical, pharmacological and therapeutic properties. 
Drugs are classified in groups at five different successively disaggregated 
levels.  The  drugs  are  divided  into  main  groups  ( first  level),  with  one 
pharmacological/therapeutic subgroup (second level). The third and fourth levels 
are chemical/ pharmacological/ therapeutic subgroups and the  fifth level is the 
chemical substance. The second, third and fourth levels are often used to identify 
pharmacological subgroups  in cases where  that is considered more appropriate 
than therapeutic or chemical subgroups.  We annotated each product with its one, 
two and three digit ATC classification. 
Specialist or Primary Care Status:   The IMS specialist (SP) driven and 
primary care (PC) driven therapy class segmentation is an assignment of SP or PC 
status respectively, based on a review of available data and IMS‘ experts‘ review 
                                                 
2 See WHO Collaborating Centre for Drug Statistics Methodology. About the ATC/DDD system.  
Available online at http://www.whocc.no/atcddd/.    CHARACTERIZING  MARKETS  FOR  BIOPHARMACEUTICAL  INNOVATIONS: 
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of predominant physician type prescribing the drug.  Classes where the majority 
of  prescribing  and  particularly  new  and  changed  prescribing  is  driven  by 
specialists or primary care physicians are assigned to one category or the other.  
This analysis allows the segmentation of sales data by the type of physician who 
most routinely makes the key decisions regarding drug prescriptions within the 
class, regardless of whether physician-specific data is available. 
FDA  Review  Classification:    Using  FDA  website  and  third  party 
published  information,  we  annotated  each  product  according  to  whether  it 
underwent a priority or standard review process. 
FDA  Orphan  Status:  Each  product‘s  orphan  status  at  the  time  of  its 
original  approval  was  researched  and  annotated.    If  supplemental  approvals 
gained orphan status but the original  NDA/BLA did  not, for this analysis  the 
product is not considered an orphan drug. 
Black Box Warning Status:  Using information originally provided on the 
FDA website as a single table regarding black box warning actions, and after 
confirming this action via sampling of our data set, we determined whether over 
the life of each product a black box warning status was ever indicated. 
sNDA  and  sBLA  History:  Using  the  IMS  Lifecycle  R&D  Focus,  we 
identified the  number and timing of  supplemental  approvals  for each product.  
IMS Lifecycle R&D Focus is a database of all active pipeline products, including 
follow-on indications of marketed products.  Our analysis was based on the dates 
of U.S. approvals of follow-on indications for the products in the core data set. 
E.  OTHER DATA 
Aggregate  product  pipeline  data  was  obtained  from  the  IMS  Lifecycle 
R&D Focus database.   
F.  STATISTICAL METHODS 
Because we observe the population universe of newly launched products, 
rather than a random sample drawn from the population universe, we do not carry 
out  traditional  statistical  inference  tests.    However,  we  compute  a  variety  of 
population means and standard deviations.     Our computations were carried out 
in Microsoft Excel, from Office 2002. 
Our commercial analyses focus on sales and price growth rather than on 
absolute prices.  We calculate such growth rates for each individual product prior 
to computing population statistics to obtain  important data quality advantages.  
Pricing  per  unit  varies  substantially  among  the  therapeutic  classes,  making CHARACTERIZING  MARKETS  FOR  BIOPHARMACEUTICAL  INNOVATIONS: 
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comparisons across classes difficult.  Dosing approach such as oral, intravenous 
infusion,  subcutaneous  injection  and  inhalation  also  vary  widely,  making 
comparisons of standard units and unit prices difficult across formulations.  A 
tableted oral drug taken four times a day carries a dramatically different price per 
dose  than  a  monthly  injection  even  if  the  price  per  patient  treatment  year  is 
identical.  Moreover, the price per patient treatment year varies among medicines.  
In addition, distribution channels and their pricing transparency vary dramatically.  
Injectable drugs and oral drugs are often covered under different medical benefit 
plan sections with differing patient co-pays, provider incentives and distribution 
margins, thereby affecting pricing and demand.   In addition, the transparency of 
the different channels for injectables, vaccines, infusions and oral drugs differ.  
For instance, oral drugs often carry rebates which are not reported to the IMS 
Health  database.    Injectables,  particularly  those  for  oncology  or  which  are 
hospital-administered, are often obtained at a discount by providers who are then 
reimbursed at the higher Average Wholesale Price or Average Sales Price.  While 
now undergoing more restrictions, such ―Buy and Bill‖ practices were prevalent 
during the examined period.  Calculating sales growth and price growth for each 
product separately self-corrects for reporting biases among these various dosing, 
distribution and reimbursement regimens.  For this reason we emphasize growth 
rates rather than absolute measures.  We emphasize average growth rates where 
the growth rates themselves are averages of individual product growth rates rather 
than a sum of product sales divided by the count of products.  While this corrects 
for the biases discussed, it also has the effect of not weighting products by their 
relative  sales-a  small  product  carries  as  much  importance  as  a  large  product.  
Thus,  the  reader  is  cautioned  on  interpreting  the  results  average  growth  rate 
results. 
III.   RESULTS 
A.  NUMBER AND COMPOSITION OF NEW PRODUCT LAUNCHES 
Over the 1998-2008 time frame, a total of 308 new biopharmaceuticals 
were launched in the U.S. market, averaging 28 per year over the eleven-year time 
period.  Of these, 212 (69%) were small molecules, and 96 (31%) were biologics.  
As shown  in  Figure and  as discussed  by  numerous others, (See, for example, 
Berndt et al., 2006 and U.S. Food and Drug Administration, 2004). there is a clear 
downward trend in the number of new biopharmaceuticals launched annually.   CHARACTERIZING  MARKETS  FOR  BIOPHARMACEUTICAL  INNOVATIONS: 
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Figure 2:  Number of Newly Launched New Molecular Entities, Small 
Molecules and Biologics, 1998-2008 
 
Table shows that between 1998 and 2003 the mean number of launches 
averaged just under 34 per year, and then fell to an average of about 21 annually 
between 2004 and 2008—a decline of about 37%.   Although the biologics share 
of total launches varies considerably across years, over multi-year periods it has 
remained remarkably stable – 31% between 1998 and 2003, and 32% from 2004 
through 2008.  The biologics share was highest in 2008  – 47% (9 of 19 new 
approvals), the final year in our investigation.   
Table 1: Mean Number of Newly Launched New Molecular Entities,  
Small Molecules and Biologics, 1998-2003, 2004-2008 
 
Over the entire eleven year period, as shown in Table, the largest number 
of new products were launched in the anti-infectives for systemic use therapeutic 
class (n=61), antineoplastic and immunomodulating agents (49), alimentary tract 
and metabolism (42), and central nervous system (37) classes; together these four 
therapeutic classes accounted for 189 of the 308 (61%) new product launches.   
Table 2:  Therapeutic Class Composition of Biopharmaceutical Innovations: 
Biologics and Small Molecules 
Percentage
98-03 04-08 98-03 04-08 Total
Biologic 10.3 6.8 31% 32% 31%
Small Molecule 23.3 14.4 69% 68% 69%
Total 33.7 21.2
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Newly launched biologics have tended, however, to be more concentrated 
in select therapeutic classes than have small molecules.  Table indicates there are 
four therapeutic classes in which ten or more new biologics have been launched:  
anti-infectives  for  systemic  use  (n=23),  antineoplastic  and  immunomodulating 
agents  (n=21),  alimentary  tract  and  metabolism  (n=16)  and  blood  and  blood 
forming organs (n=16).  In comparison, ten or more new small molecules have 
been launched in nine of the 15 therapeutic classes.  While new small molecule 
launches  occurred  in  14  of  15  therapeutic  classes  (only  systemic  hormonal 
preparations  had  no  new  small  molecule  product  launches),  no  new  biologics 
were  launched  in  three  classes  –  genito-urinary  systems  and  sex  hormones, 
intravenous solutions and antiparasitic products.   
The biologics share of new biopharmaceutical products is highest in the 
blood and blood forming organs class at 73% (16 of 22), but is also substantial in 
oncology  at  43%  (antineoplastic  and  immunomodulating  agents,  21/49).      By 
contrast, small molecules strongly dominate among central nervous system new 
product launches (36/37), cardiovascular (20/21), genito-urinary systems and sex 
hormones  (13/13),  respiratory  system  (11/12)  and  the  ―various  other‖  class 
(11/12). 
ATC Classification Biologic  Small Molecule  Total
A: Alimentary Tract and Metabolism 16 26 42
B: Blood and blood forming organs 16 6 22
C: Cardiovascular System 1 20 21
D: Dermatologicals 3 5 8
G: Genito-Urinary Systems and Sex Hormones 13 13
H: Systemic Hormonal Preparations, Excl. Sex Hormones And Insulins 7 7
J: Anti-Infectives For Systemic Use 23 38 61
K: Intravenous Solutions 1 1
L: Antineoplastic And Immunomodulating Agents 21 28 49
M: Musculo-Skeletal System 4 6 10
N: Nervous System 1 36 37
P: Antiparasitic Products 1 1
R: Respiratory System 1 11 12
S: Sensory Organs 2 10 12
V: Various 1 11 12
Total 96 212 308CHARACTERIZING MARKETS FOR BIOPHARMACEUTICAL INNOVATIONS: DO BIOLOGICS DIFFER FROM SMALL 
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Table 3:  Therapeutic Class Concentration of Biopharmaceutical Innovations: Biologics and Small Molecules 
 
Biologic Rank Ordered Therapeutic Classes Small Molecule Rank Ordered Therapeutic Classes
ATC Classification Biologic  Cumulative Percent ATC Classification Small Molecule  Cumulative Percent
J: Anti-Infectives For Systemic 
Use 23 24%
J: Anti-Infectives For Systemic 
Use 38 18%
L: Antineoplastic And 
Immunomodulating Agents 21 46% N: Nervous System 36 35%
A: Alimentary Tract and 
Metabolism 16 63%
L: Antineoplastic And 
Immunomodulating Agents 28 48%
B: Blood and blood forming 
organs 16 79%
A: Alimentary Tract and 
Metabolism 26 60%
H: Systemic Hormonal 
Preparations, Excl. Sex 
Hormones And Insulins 7 86% C: Cardiovascular System 20 70%
M: Musculo-Skeletal System 4 91%
G: Genito-Urinary Systems 
and Sex Hormones 13 76%
D: Dermatologicals 3 94% R: Respiratory System 11 81%
S: Sensory Organs 2 96% V: Various 11 86%
C: Cardiovascular System 1 97% S: Sensory Organs 10 91%
N: Nervous System 1 98%
B: Blood and blood forming 
organs 6 94%
R: Respiratory System 1 99% M: Musculo-Skeletal System 6 97%
V: Various 1 100% D: Dermatologicals 5 99%
G: Genito-Urinary Systems 
and Sex Hormones 100% K: Intravenous Solutions 1 100%
K: Intravenous Solutions 100% P: Antiparasitic Products 1 100%
P: Antiparasitic Products 100%
H: Systemic Hormonal 
Preparations, Excl. Sex 
Hormones And Insulins 100%
Total 96 Total 212CHARACTERIZING  MARKETS  FOR  BIOPHARMACEUTICAL  INNOVATIONS: 
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Table  3  documents  that  biologics  are  more  concentrated  than  small 
molecules.    The  concentration  of  new  biologics  in  their  top  four  therapeutic 
classes is substantial, accounting for almost 80% of the new biologic launches (76 
of the 96 biologics).   By contrast the top four small molecule therapeutic classes 
contain only 60% of the new small molecule NMEs. 
Nonetheless, the fact that new biologics have been introduced in a wide 
variety of therapeutic classes reflects the breadth of their clinical applicability and 
suggests  that  the  future  composition  of  new  biologics  might  diffuse  more 
generally, differing considerably from that observed historically.   In this context, 
in Figure 3 divides the data set into two periods, 1998-2002 and 2003-2008.   In 
the  latter  period  biologics  are  present  in  three  additional  therapeutic  areas 
(nervous system, respiratory system and sensory organs) while losing presence in 
the  cardiovascular  system  therapeutic  area.    Over  the  period  the  top  four 
therapeutic area biologics concentration falls from 83% to 75%.   We comment 
briefly on pipeline composition later on in this article. 
Figure 3:  Biologic Therapeutic Distributions Change Over Time 
 
0 2 4 6 8 10 12 14
A: Alimentary Tract and Metabolism
B: Blood and blood forming organs
C: Cardiovascular System
D: Dermatologicals
G: Genito-Urinary Systems and Sex Hormones
H: Systemic Hormonal Preparations, Excl. Sex Hormones  …
J: Anti-Infectives For Systemic Use
K: Intravenous Solutions
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We now digress briefly to examine in greater detail the four therapeutic 
classes in which the most new biologics have been launched.  As seen in Figure , 
among  the  infectious  disease  class,  while  new  antibacterials  and  antimycotics 
(antifungals)  are  entirely  small  molecules  (as  historically  have  been  all  the 
penicillins), the antivirals (including AIDs medicines) are a mix of biologics and 
small molecules.   By contrast, the various immune sera and immunoglobulins 
(circulating  antibodies)  and  prophylactic  vaccines  have  no  small  molecule 
analogs, and are therefore entirely comprised of new biologics.  Note that over the 
1998-2008 timeframe, 14 new vaccines were launched. 
Figure 4:  Product Distribution Within ATC J, Infectious Disease 
 
Figure  decomposes the  various  cancer-related  new products  into three 
subcategories.    Among  the  antineoplastic  and  endocrine  therapy  agents,  there 
have  been  both  substantial  new  biologics  (12/38)  and  new  small  molecules 
(26/38), reflecting the fact that different mechanisms have been pursued to disrupt 
binding at receptor sites; notably, among the new small molecules is Novartis‘ CHARACTERIZING  MARKETS  FOR  BIOPHARMACEUTICAL  INNOVATIONS: 
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Gleevec  (imatinib  mesylate)  tablet,  one  of  the  ―poster  children‖  of  the  new 
―personalized medicines‖.   For a discussion of targeted, personalized or what we 
have called stratified medicines, see Calfee and DuPre (2006), and Trusheim, et 
al. (2007).  All three new immunostimulants are biologics, as are six of the eight 
new immunosuppressive agents. 
Figure 5:  Product Distribution Within ATC L, Oncology 
 
The  digestive  and  metabolic  therapeutic  class  (alimentary  tract  and 
metabolism) includes a wide variety of conditions, as shown in Figure .  Among 
new  products  used  in  treating  diabetes,  six  are  biologics  and  six  are  small 
molecules.  A fascinating set of biologics are the monoclonal antibodies which 
modulate inflammation.  These biologics can manifest their effects in seemingly 
disparate  conditions,  see  Reichert  (2005)  and  Reichert  and  Paquette  (2003).  
Centocor‘s  Remicade  (infliximab),  for  example,  while  originally  approved  for 
rheumatoid arthritis, is now also approved for Crohn‘s disease (a gastrointestinal 
condition), ankylosing spondylitis (a spine and joint illness often also affecting 
the eyes and heart, and co-occuring with inflammatory bowel disease),
3 psoriatic 
                                                 
3 See ―ankylosing spondylitis‖ in Anderson, Anderson and Glanze [1998], pp. 94-95. CHARACTERIZING  MARKETS  FOR  BIOPHARMACEUTICAL  INNOVATIONS: 
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arthritis,  plaque  psoriasis,  and  ulcerative  colitis.
4    Other monoclonal antibody 
biologics with a diverse set of FDA indication approvals include Abbott‘s Humira 
(adalimumab) and Amgen‘s Enbrel (etanercept).
5  It is worth emphasizing here 
that  although  supplementary  indication  approvals  granted  by  the  FDA  can 
constitute  very  important  and  significant  innovations,  because  these  FDA 
approvals are typically granted subsequent to the initial new Biologics License 
Application or New Drug Application approval, they are typically not counted as 
―new  products‖  when  tallying  up  the  number  of  new  product  approvals  or 
launches annually.
6  For discussion of review time to initial NME FDA approval 
relative to review time from sNDA/sBLA application to supplemental approval, 
see Berndt et al. (2006), Gosse and Nelson (1997), and Gosse et al. (1996).   We 
comment on supplementary indications for biologics in further detail below.     
Figure 6:  Product Distribution Within ATC A, Metabolic 
 
                                                 
4 See ―Remicade‖ in Physicians‘ Desk Reference [2009], p. 954. 
5 See ―Etanercept‖ and ―Adalimumab‖ in Drug Facts and Comparisons [2008], pp. 2453-2461. 
6 In some cases the number of patients affected by a supplementary approval is considerably larger 
than those benefiting from the original indication.  For examples and further discussion, 
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The fourth largest number of new biologics is found in the hematologic 
(blood  and  blood  forming  organs)  class;  this  is  the  only  class  in  which  new 
biologics dominate small molecules (16 of 22).  As seen in Figure , of the 13 
antithrombic  (anticlotting)  agents,  nine  are  biologics,  and  four  are  small 
molecules.  Although smaller in absolute numbers, biologics also comprise the 
predominant share of new antihemorrhagics (six of seven) – products used to treat 
hemophilia and other blood loss conditions.  The ―other hematological agents‖ 
subcategory includes second generation erythropoietin (―epo‖) products, such as 
Amgen‘s Aranesp (darbepoietin alfa) used for treatment of anemia. 
Before leaving this section and moving on to discuss the significance of 
innovation embodied in new biopharmaceuticals, we comment on relative delays 
following FDA approval  but before  launch of the  new product and the  initial 
recording of sales revenues.  There are several sources of launch delays that can 
occur  following  FDA  new  product  approval.    First,  quite  frequently  there  is 
considerable discussion between the FDA and the new biopharmaceutical sponsor 
involving  the  precise  wording  that  will  appear  on  the  product  label  (also 
frequently called the product insert).   
Figure 7:  Product Distribution Within ATC B, Hematologic 
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Second, occasionally companies experience manufacturing difficulties and 
delays in scaling up their production from clinical to commercial levels.  Since 
manufacturing  complexities  are  generally  thought to  be  more  common  among 
biologics than small molecules, one might conjecture that delays between FDA 
approval and actual product launch are likely to be greater for biologics.  Finally, 
sponsoring companies may need to prepare marketing materials and train sales 
representatives for the new product launch, and since date of FDA approval is 
uncertain,  training  sales  representatives  with  material  containing  approved 
labeling may delay the launch date.  We quantify the launch delay as the number 
of days between FDA product approval and the date at which new product sales 
revenues are first observed by IMS Health‘s shipment invoicing data.
7 
Table    presents  average  days  delay  between  FDA  approval  and  first 
observed  sales,  by  therapeutic  class,  separately  for  biologics  and  for  small 
molecules, and then for all new biopharmaceuticals.  As seen in the bottom row of 
Table , mean days delay for biologics is 58.7, about a week less than the 65.1 
mean delay for small molecules.  Given the very large standard deviations (above 
100), this one week difference is not significant.  These apparent similarities in 
days  delay  between  biologics  and  small  molecules  mask,  however,  very  large 
difference within certain therapeutic classes.   In class  A (alimentary tract and 
metabolism), for example, the average delay for biologics is about four months 
(128 days), twice that for small molecules (63 days); in class B (blood and blood 
forming agents), however, the reverse occurs – for biologics the mean delay is 61 
days,  less  than  half  that  for  small  molecules  (166  days).    This  striking 
heterogeneity is also observed in other therapeutic classes.    Given the small 
number of products in each class, the means are often driven by a lengthy delay 
by one or two products in the class.  This is reflected in the very large standard 
deviations in these classes which make the apparent mean differences statistically 
insignificant.  An understanding of whether the hypothesized causes  for delay 
occurred, to what extent and in which classes is not suggested by this data and 
would require  individual  investigations of specific  cases, which  is  beyond the 
scope of this article.  The data do, however, clearly indicate that a wide range of 
delays occurs with 56% (172) having a mean delay of a month or less and 13 
having a mean delay of more than one year. 
                                                 
7 When a new product‘s sales revenues are first observed by IMS Health, we set the date to the 
15
th of that month.  As a result, it is possible for a launch delay to be negative (if, for 
example, the product received FDA approval after the 15
th of that month, and sales were 
observed by IMS Health during that month). CHARACTERIZING MARKETS FOR BIOPHARMACEUTICAL INNOVATIONS: DO BIOLOGICS DIFFER FROM SMALL 
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Table 4: Days Delay Between FDA Approval and First Observed Sales by ATC Class, Biologics and Small 
Molecules 
 
ATC1 Mean Std. Dev. Count Mean Std. Dev. Count Mean Std. Dev. Count
A: Alimentary Tract and Metabolism 128.3 196.0 16.0 63.3 152.7 26.0 88.0 171.2 42.0
B: Blood and blood forming organs 60.7 95.9 15.0 166.0 301.8 6.0 90.8 177.7 21.0
C: Cardiovascular System -9.0 1.0 95.8 164.6 20.0 90.8 162.1 21.0
D: Dermatologicals 7.7 7.4 3.0 110.6 101.6 5.0 72.0 93.6 8.0
G: Genito-Urinary Systems and Sex Hormones 52.1 99.5 13.0 52.1 99.5 13.0
H: Systemic Hormonal Preparations, Excl. Sex 
Hormones And Insulins 117.7 79.3 6.0 117.7 79.3 6.0
J: Anti-Infectives For Systemic Use 42.4 50.5 23.0 27.5 86.5 38.0 33.1 74.8 61.0
K: Intravenous Solutions 154.0 1.0 154.0 1.0
L: Antineoplastic And Immunomodulating Agents 17.7 22.9 20.0 9.3 31.9 28.0 12.8 28.5 48.0
M: Musculo-Skeletal System 28.5 37.3 4.0 124.2 261.3 6.0 85.9 202.0 10.0
N: Nervous System 155.0 1.0 56.1 79.2 36.0 58.8 79.8 37.0
P: Antiparasitic Products 99.0 1.0 99.0 1.0
R: Respiratory System 11.0 1.0 142.3 179.2 11.0 131.3 175.0 12.0
S: Sensory Organs 8.0 9.9 2.0 34.5 86.4 10.0 30.1 78.9 12.0
V: Various 154.0 1.0 162.3 179.2 11.0 161.6 170.9 12.0
Grand Total 58.7 103.6 93.0 65.1 133.0 212.0 63.2 124.6 305.0
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B.  INNOVATION:  NDAs, BLAs AND SUPPLEMENTAL APPROVALS 
It  is  difficult  if  not  impossible  to  quantify  reliably,  objectively  and 
unambiguously the extent to which new biopharmaceuticals embody significant 
innovation  and  address  unmet  medical  needs.    With  that  caveat  in  mind,  we 
nevertheless  examine  three  metrics  that  provide  some  information  on  the 
significance of the biopharmaceutical innovation, and then compare new biologics 
and small molecules on these metrics. 
In 1983 the U.S. Congress passed the Orphan Drug Act P. L. 97-414 that 
provides market exclusivity, protocol assistance and grant funding in connection 
with the development of drugs  for rare diseases and conditions.  The original 
definition of ―rare disease or condition‖ in the Orphan Drug Act was amended in 
October 1984 by P.L. 98-551 to add a specific numeric prevalence threshold to 
the  condition:    ―…the  term  rare  disease  or  condition  means  any  disease  or 
condition which (a) affects less than 200,000 persons in the U.S. but for which 
there  is  no  reasonable  expectation  that  the  cost  of  developing  and  making 
available in the U.S. a drug for such disease or condition will be recovered from 
sales in the U.S. of such drug.‖ U.S. Food and Drug Administration (2009a).   A 
sponsor may apply for Orphan Drug designation along with its Biologics License 
Application (―BLA‖) or its New Drug Application (―NDA‖), but it can also apply 
for  Orphan  Drug  designation  as  part of  a  supplementary  BLA  or  NDA  for  a 
previously approved biopharmaceutical. 
As seen in Table , a non-trivial portion, 17% (51 of 308) of all newly 
approved biologics and small molecules between 1998 and 2008 were designated 
as Orphan Drugs at the time of initial approval.
8  Interestingly, the portion of new 
biologics receiving Orphan Drug designation (24%, 23 of 96) was almost twice as 
large as that for small molecules (13%, 28 of 212).  That one of about every eight 
newly approved  small molecules  treats a rare condition is a testimony to the 
beneficial and powerful incentives provided by the Orphan Drug legislation.  That 
this proportion is almost twice as large  at 24% for biologics is surprising and 
remarkable. 
A  second  indicator  of  the  potential  significance  of  the  innovation 
embodied in a new biopharmaceutical is the review status assigned to the NDA or 
                                                 
8 We also observe that numerous biologics and small molecules received Orphan Drug designation 
on the supplementary BLA or supplementary NDA applications.  We are unaware of any 
studies that have examined and quantified the extent to which, and timing of, Orphan 
Drug designation through the product life cycle of a small molecule or biologic.  CHARACTERIZING  MARKETS  FOR  BIOPHARMACEUTICAL  INNOVATIONS: 
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BLA by the FDA at the time the application is submitted by the sponsor.  In 1992, 
under the Prescription Drug User Fee Act (―PDUFA‖) legislation, Congress and 
the FDA agreed on a two-tier  system of review times -- standard review and 
priority review.  Standard review is applied to a drug that offers at most, only 
minor improvement over existing marketed therapies.  The 2002 amendments to 
PDUFA  set  a  goal  that  a  standard  review  of  an  NDA/BLA  application  be 
accomplished within a ten-month time frame.  A priority review designation is 
given  to  drugs that offer  major  advances  in  treatment, or  provide  a  treatment 
where no adequate therapy exists.  Under the 2002 amendments to PDUFA, the 
goal for the FDA completing a priority review is six months, U.S. Food and Drug 
Administration  (2009b).    A  substantial  portion,  but  not  all  Orphan  Drug 
designations are also given priority review status. 
Table 5:  Orphan, Priority and Supplemental Reviews 
   
In the middle panel of Table  we tabulate review status, separately for 
biologics and small molecules, and in total.  Altogether, 40% (124/308) of new 
Biologic Small Molecule Grand Total
Orphan
  Number 23 28 51
  Percentage 24% 13% 17%
Priority Review
  Number 42 82 124
  Percentage 44% 39% 40%
Priority Review Adjusted for Vaccines & Insulins
  Number 40 82 124
  Percentage 49% 39% 40%
Mean Supplementals 0.75 0.66 0.69
Total Therapeutics 96 212 308
Total Therapeutics Adjusted for Vaccines & Insulins
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product approvals between 1998 and 2008 were granted priority review status.
9  
The difference between biologics and small molecules in priority review status 
also  occurs,  but  is  much  smaller  th an  for  the  Orphan  Drug  designation.  
Specifically, while 44% of biologics were given priority review status, a very 
respectable 39% of approved small molecule applications  were assigned priority 
review.   
Biologics include many novel therapeutics, but they  also include insulin 
products and vaccines which rarely receive priority reviews.  In the bottom of the 
middle panel we remove these biologic classes and recalculate the priority review 
percentages.  Fourteen products are removed, only two of which (both  vaccines) 
received priority review.  This raises the percentage of biologics receiving priority 
review to nearly half (40 of 82, or 49%).   
A final metric involving quantification of innovation involves the extent to 
which biologics and small molecules secured supplemental indication approvals.  
Above we noted that particularly for some of the biologic monoclonal antibodies, 
the range of disease/condition approvals eventually received by the sponsor  has 
been remarkably large. 
In  the  bottom  panel  of  Table    we  tabulate  the  mean  number  of 
supplemental approvals obtained by newly approved biopharmaceutical products 
between  1998  and  2008.    Over  all  new  products,  the  mean  number  of 
supplemental approvals is 0.69; for biologics, however, this average at 0.7 5 is 
slightly greater than that for small molecules at 0.66.
10     
As shown in Table, when examined by therapeutic area, the gap between 
biologics and small molecules is particularly large among the alimentary tract and 
metabolism agents, where the mean number of supplemental approvals over 16 
biologics is 1.31, about twice the 0.62 for the 26 small molecules.  Similarly, for 
the blood and blood forming organs class, the mean numb er of supplemental 
approvals for the 16 biologics was 0.88, more than twice the 0.33 for the six small 
molecules.  On the other hand, among the anti -infectives for systemic use, on 
                                                 
9 For an earlier examination of whether priority review rates drugs were approved more quickly by 
the FDA, see Dranove and Meltzer (1994). 
10 Initially this mean number of supplemental indications appeared unreasonably small.  However, 
a manual check of the R&D Focus data base entries for several biologics and comparison 
with FDA Orange Book approval data revealed no undercounting.  We intend to examine 
supplemental approvals more deeply in subsequent research. CHARACTERIZING  MARKETS  FOR  BIOPHARMACEUTICAL  INNOVATIONS: 
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average the 38 small molecules had 0.61 supplementary approvals, substantially 
more than the 0.35 for biologics.  This last disparity may be accounted for by the 
fact  that  the  biologics  focus  on  HIV  treatment  whereas  the  small  molecules 
contain  a  substantial  number  of  general  antibiotics  and  antifungals,  thereby 
having greater inherent ability to secure multiple indications. 
In  summary,  on  the  basis  of  three  distinct  indicators  of  embodied 
innovation – Orphan Drug designation, priority review status and mean number of 
supplemental  approvals,  biologics  rank  higher  than  small  molecules,  although 
only  in  the  case  of  Orphan  Drug  designation  is  this  superiority  ranking 
substantial. CHARACTERIZING MARKETS FOR BIOPHARMACEUTICAL INNOVATIONS: DO BIOLOGICS DIFFER FROM SMALL 
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Table 6:  Supplemental NDAs by ATC Class 
 
ATC1 Mean Std. Dev Mean Std. Dev Mean Std. Dev
A: Alimentary Tract and Metabolism 1.31 1.30 0.62 0.85 0.88 1.09
B: Blood and blood forming organs 0.88 0.81 0.33 0.52 0.73 0.77
C: Cardiovascular System 1.00 0.90 0.55 0.90 0.54
D: Dermatologicals 0.67 0.58 0.60 0.55 0.63 0.52
G: Genito-Urinary Systems and Sex Hormones 0.62 0.65 0.62 0.65
H: Systemic Hormonal Preparations, Excl. Sex 
Hormones And Insulins 0.29 0.49 0.29 0.49
J: Anti-Infectives For Systemic Use 0.35 0.78 0.61 0.59 0.51 0.67
K: Intravenous Solutions 0.00 0.00
L: Antineoplastic And Immunomodulating Agents 0.86 1.24 0.79 0.69 0.82 0.95
M: Musculo-Skeletal System 0.50 0.58 0.67 0.52 0.60 0.52
N: Nervous System 1.00 0.72 1.09 0.73 1.07
P: Antiparasitic Products 1.00 1.00
R: Respiratory System 1.00 0.73 0.65 0.75 0.62
S: Sensory Organs 1.00 0.00 0.30 0.48 0.42 0.51
V: Various 0.00 0.45 0.52 0.42 0.51
Grand Total 0.75 0.99 0.66 0.73 0.69 0.82
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C.  SAFETY ASPECTS 
Whether biologics or small molecules have differing safety track records 
is  not obvious a priori.  One  metric commonly employed  by observers  is the 
extent to which approved products are assigned black box warnings by the FDA, 
the  most  stringent  warning  the  FDA  can  give  without  entirely  removing  the 
product from the marketplace. 
In Table  we tabulate rates at which newly approved biologics and small 
molecules  have  been  required  to  place  black  box  warnings  on  their  product 
labeling by the FDA.  As is seen there, over all new biopharmaceuticals, 22% (67 
of 308) have placed black box warnings on their label.  Moreover, at 26% (25/96) 
this proportion is slightly greater for biologics than for small molecules at 20% 
(42/212).    As noted above, biologics are concentrated in fewer therapeutic areas 
than are small molecules.  To adjust partially for therapeutic area biases, we also 
tabulated the black box warning rates for the top four biologic therapeutic areas.  
The biologics rate falls to 25% (19/76) while the small  molecule rate remains 
relatively  stable  at  19%  (19/98).    Again,  the  proportion  of  biologics  remains 
slightly greater than that for small molecules. 
Table 7:  Safety: Black Box Warning Experience 
 
 
A  different  safety-related  metric  involves  calculating  the  proportion  of 
new biopharmaceuticals that subsequently permanently exited the market.  The 
exit could be for safety reasons, as was the case for small molecules Bextra and 
Vioxx and for the biologic vaccine Rotashield, or for related commercial reasons, 
as was the case for GlaxoSmithKline‘s lyme disease vaccine, LymeRx, On this, 
All Products
Biologic Small Molecule Total
Number 25 42 67
Percent 30% 20% 22%
Top Four Biologics Areas (A, B, J, L)
Biologic Small Molecule Total
Number of Warnings 19 19 38
Total Products 76 98 174
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see Berndt, Denoncourt and Warner (2009).  Since reasons for product exit may 
be  difficult  to  determine  in  an  objective  and  replicable  manner,  we  simply 
compute the proportion of newly approved products that eventually permanently 
exited  the  marketplace,  where  exit  was  determined  by  the  IMS  Health‘s  data 
reporting that product sales revenues, while  non-zero earlier, were zero in the 
final months of 2008.    
As seen in Table, over all newly approved biopharmaceuticals between 
1998  and  2008,  8.8%  (27/308)  had  exited  the  market  by  the  end  of  2008.  
Moreover, at 9.4% (20/212) this proportion is slightly greater for small molecules 
than the 7.3% (7/96) for biologics.  Notably, among vaccines this attrition rate 
was particularly high; of the fourteen vaccines approved between 1998 and 2008, 
three (Certiva, LymeRx and Rotashield, or 21.4%) eventually exited the market.  
Excluding the 14 vaccines from all biologics leaves only 4.9% of non-vaccine 
biologics (4/82) exiting the market permanently.   
Table 8:  Product Exits 
 
A  related  safety  aspect  involves  the  characteristics  of  the  physician 
prescribing the new product.  A plausible hypothesis is that biologics are more 
complex new medications, whose administration by injection or infusion is more 
likely to be carried out at least initially by specialist (―SPs‖) rather than primary 
care (―PC‖) physicians.
11  However, since vaccines are biologics and are largely 
prescribed by PCs, the extent to which biologics are disproportionately prescribed 
by SPs is unclear. 
Based on global data, IMS Health classifies physician prescriber type at a 
very  detailed  Anatomical  Therapeutic  Classification  basis.    As  seen  in  
                                                 
11 For related discussion and some recent evidence, see Aitken et al. (2008). 
Biologic Small Molecule Total
Number 7 20 27
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Table, over all new biopharmaceuticals, 46% of newly approved products 
are  prescribed  predominantly  by  primary  care  physicians,  while  54%  are 
prescribed  predominantly  by  specialists.    There  is,  however,  a  substantial 
difference in PC/SP prescribing shares between small molecules and biologics.  
While PCs predominantly prescribe 53% of the newly approved small molecules, 
they  are  the  predominant  prescribers  of  only  32%  of  the  newly  launched 
biologics.  We further observe in the detailed data in the lower panel of the Table 
9 that among biologics, the disproportionate SP share is falling slightly, from an 
average of 69% 1998-2003 to 65% in 2004-2008.  Interestingly, among small 
molecules the SP trend is reversed.  Specifically, the SP share of predominantly 
prescribed new small molecules is increasing, from 46% 1998-2003 to 49% 2004-
2008. 
D.  PRODUCT COMMERCIAL EXPERIENCE ANALYSIS 
We now shift to examine the similarities and differences among biologics 
and  small  molecules  during  their  launch  phase  and  subsequent  commercial 
periods over their product life cycles.  We have sales, volume and derived price 
(sales  /  volume)  data  from  products  newly  launched  between  1998  and  2008.  
Rather  than  take  a  calendar  year  perspective  we  aligned  each  product‘s  data 
according to its relative time from the quarter of its first observed U.S. revenues.  
For those products first sold in the first quarter of 1998, we have up to 44 quarters 
of sales revenue data, whereas for those newly approved in 2008, we have at most 
four quarters of sales revenue data.  Note that no product first launched in the U.S. 
during or after 1998Q1 had lost patent protection by the end of our maximum 
eleven-year time period, 2008Q4, and therefore there are no generic products in 
this product life cycle analysis.     
As Figure illustrates, the time series nature of the launches displays itself 
as a monotonically declining number of products in each period as one moves 
away from the launch date.  We have 299 initial product observations for sales 
revenue in the first quarter (Quarter 1), 185 in Quarter 20 and 38 in Quarter 40.  
In Quarter 33 the number of biologic products with data falls below 20.  Due to 
this small number of products, we restrict the following analysis to the periods 
from Quarter 1 through Quarter 32. CHARACTERIZING MARKETS FOR BIOPHARMACEUTICAL INNOVATIONS: DO BIOLOGICS DIFFER FROM SMALL 
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Table 9:  Specialist and Primary Care Predominant Prescriber 
 
 
   
Count Percentage Count Percentage Count Percentage
Primary Care Driven ATCs 31 32% 112 53% 143 46%
Specialist Driven ATCs 65 68% 100 47% 165 54%
Grand Total 96 212 308
Grand Total Biologic Small Molecule
Product TypeSpecialty or Primary Care 98-03 04-08
Biologic Primary Care Driven ATCs 31% 35%
Specialist Driven ATCs 69% 65%
Biologic Total 14 7
Small Molecule Primary Care Driven ATCs 54% 51%
Specialist Driven ATCs 46% 49%
Small Molecule Total 32 29
Grand Total 46 36
Product TypeSpecialty or Primary Care 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007 2008 Grand Total
Biologic Primary Care Driven ATCs 3 2 3 6 3 2 1 3 4 4 31
Specialist Driven ATCs 11 5 3 7 5 12 5 3 6 3 5 65
Biologic Total 14 7 6 13 8 14 6 6 10 3 9 96
Small Molecule Primary Care Driven ATCs 18 18 7 11 13 8 8 5 9 8 7 112
Specialist Driven ATCs 14 11 18 7 7 8 7 9 8 8 3 100
Small Molecule Total 32 29 25 18 20 16 15 14 17 16 10 212
Grand Total 46 36 31 31 28 30 21 20 27 19 19 308
Product TypeSpecialty or Primary Care 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007 2008 Grand Total
Biologic Primary Care Driven ATCs 21% 29% 50% 46% 38% 14% 17% 50% 40% 0% 44% 32%
Specialist Driven ATCs 79% 71% 50% 54% 63% 86% 83% 50% 60% 100% 56% 68%
Biologic Total
Small Molecule Primary Care Driven ATCs 56% 62% 28% 61% 65% 50% 53% 36% 53% 50% 70% 53%
Specialist Driven ATCs 44% 38% 72% 39% 35% 50% 47% 64% 47% 50% 30% 47%
Small Molecule Total
Grand TotalCHARACTERIZING MARKETS FOR BIOPHARMACEUTICAL INNOVATIONS: DO BIOLOGICS DIFFER FROM SMALL 
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Figure 8:  Count of 1998-2008 NMEs by Quarter from Launch Date 
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E.  PRICING OVER THE PRODUCT LIFE CYCLE 
We  now  turn  to  consider  several  of  the  economic  characteristics 
potentially differentiating biologics from small molecules.      The conventional 
wisdom regarding pricing of biologics vs. small molecules typically focuses on 
very high launch price levels for biologics, particularly those focused on treatment 
for cancer, although Gleevec, a small molecule, costs over $25,000 per treatment 
episode, 
1 On this, see Aitken et al. (2008).  It is challenging  to compare price 
levels between  biologics and small molecules  –  treatment  episodes  differ  in 
length, and comparison of treatment costs for episodic vs. chronic conditions is 
problematic.  Instead of level, we focus on the  price growth rate for the same 
molecule over time.  After  launching at an initial price, do prices of biologics 
increase less or more rapidly than prices of small molecules? 
Our  measure  of  relative  price  growth  is  not  without  some  ambiguity, 
however, since for a given molecule the dosage strengths per standard unit can 
vary,  and  change  over  time.    Nonetheless,  bearing  these  caveats  in  mind,  we 
compute unweighted arithmetic  mean annualized (quarter over previous  year‘s 
same quarter) growth rates in real prices, over all therapeutic classes, separately 
for biologics and small molecules.  It is worth stressing that this unweighted mean 
annualized  growth  rate  calculation  in  real  prices  is  quite  different  from  price 
indexes  computed  by,  for  example,  the  U.S.  Bureau  of  Labor  Producer  Price 
Index program.
12  Results of this calculation are given in Figure .   
  The most striking, and to us surprising , finding displayed in  Figure  is 
that over the product life cycle, in most quarters and especially between quarters 9 
and 32 (years three through eight), mean rea l price increases are substantially 
larger for small molecules than for biologics.   
We also note that small molecules experience a generally rising rate of 
price growth increases from Quarter 9 through Quarter 18 followed by a decline 
in rate of price gro wth from Quarter 19 through Quarter 32.    While biologic 
price growth fluctuates from quarter to quarter, no similar trending is obvious. 
This higher price growth phenomenon for small molecules is a most 
surprising and intriguing finding, for which we have no obvious explanation.   
                                                 
12 For a discussion of price index calculation procedures and their interpretation in the context of 
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Figure 9:  Mean Real Price Growth (Quarter over Prior Year’s Same Quarter) from First Quarter of Observed 
Revenues, Biologics and Small Molecules CHARACTERIZING  MARKETS  FOR  BIOPHARMACEUTICAL  INNOVATIONS: 
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F.  SALES REVENUES OVER THE PRODUCT LIFE CYCLE 
What we are interested in is comparing inflation-adjusted (based on the 
Gross Domestic Product implicit deflator) sales revenue data over the up to 32-
quarter product life cycle, separately for biologics and small molecules.   
Bearing the funnel nature of our data set in mind, in Figure  we plot the 
mean sales from first quarter of observed revenues over all therapeutic classes, 
separately  for biologics and small  molecules.   Four findings  from  Figure  are 
particularly noteworthy.   
First, both biologics and small molecules initially reach a mean of about 
$100 million in GDP deflated real quarterly sales revenues around quarters 21-22, 
i.e., after being on the market slightly more than five years.  This equal time to 
$100 million in mean real sales revenues is a most surprising result, given the 
conventional  wisdom  that  biologics  predominantly  tend  to  be  small-revenue 
products.   
Second, although the time to $100 million in quarterly inflation adjusted 
sales is very similar for biologics and small molecules, the path by which they 
arrive there is very different.  As seen in Figure , in the first 3-4 years on the 
market,  small  molecules  have  greater  mean  quarterly  sales  revenues  than  do 
biologics, but around quarters 17-18 this gap begins to decline, and essentially it 
is closed by quarters 21-22.  While the slope in the sales revenue line for biologics 
is  relatively  constant  up  through  quarters  21-22,  for  small  molecules  it  is 
increasing until about quarters 13-14, and then begins to decline. 
Third, after quarter 25 the mean real sales revenue of both biologics and 
small molecules has no distinct trend and is essentially flat. 
Fourth, during quarters 21 through 32, mean sales revenue for biologics is 
consistently larger than that for small molecules, although there is considerable 
variation in their relative values.    
Another way of viewing the ―rapid start‖ phenomenon for small molecules 
and ―late bloomer‖ phenomenon for biologics is by computing mean annualized 
growth rates (quarter over same quarter in previous year) in real sales revenues, 
rather than real sales revenue levels.  The results of such an empirical exercise are 
given  in  Figure .  Mean annualized real sales growth rates are plotted on the 
vertical axis, whereas quarter since first observed sales revenue is plotted on the 
horizontal axis.  Up until about quarter 15 the red curve corresponding to small 
molecules  is  above  the  blue  curve  corresponding  to  biologics,  but  thereafter, 
especially after around quarter 25, the blue curve is more often than not above the CHARACTERIZING  MARKETS  FOR  BIOPHARMACEUTICAL  INNOVATIONS: 
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red one, indicating greater late product life growth in mean real sales revenues for 
biologics than for small molecules. 
The extent to which this differential late in product life cycle growth in 
real  sales  revenues  for  biologics  reflects  relative  increases  in  supplemental 
indication approvals, lower rates of product exit, and/or the cumulative impacts of 
more specialist-intensive prescribing, is unclear, but clearly of great interest, and 
worthy of further research.  CHARACTERIZING MARKETS FOR BIOPHARMACEUTICAL INNOVATIONS: DO BIOLOGICS DIFFER FROM SMALL 
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Figure 10:  Mean Inflation Adjusted Sales from First Quarter of Observed Revenues, All ATC Classes, Biologics 
and Small Molecules 
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Figure 11:   Mean Real Sales Growth (Quarter over Prior Year’s Same Quarter) from First Quarter of 
Observed Revenues, All ATC Classes, Biologics and Small Molecules 
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IV.  DISCUSSION 
A.  SUBSTITUTES,  DISRUPTIVE  ENTRIES  OR  DIFFERENTIATED 
COMPETITORS? 
Biologics  and  small  molecules  are  usually  considered  substantially 
different  types  of  products—perhaps  as  dissimilar  from  each  other  as  they 
themselves  are  from  medical  devices.    From  a  scientific,  regulatory  and 
manufacturing  perspective  this  would  appear  true.    Our  analyses  have  shown, 
however,  that  from  a  commercial  perspective,  biologics  and  small  molecules 
share substantially similar experiences during their first 32 quarters after launch, 
while also exhibiting intriguing differences in key commercial behaviors such as 
initial adoption and late stage price and sales revenue growth.  
In  retrospect,  the  similarities  of  commercial  experience  may  not  be  as 
surprising  since  in  many  therapeutic  areas  (but  not  including  vaccines,  for 
instance),  biologics  and  small  molecule  therapies  are  increasingly  highly 
substitutable products from the perspective of physicians and patients selecting 
treatments and payers evaluating reimbursement policies.  Understanding these 
substitution  behaviors  and  limitations  should  provide  an  important  forcus  for 
future investigations.  Relaxing the assumption that each product is independent 
of the others, and is independent of products launched prior to 1998, might also 
provide greater insight into the dynamics of mixing biologics and small molecule 
modalities  in  a  given  therapeutic  indication.    Important  questions  to  examine 
include:  Does the entry of a biologic into a market perform like a disruptive 
technology, or does it behave more similarly to a highly substitutable product?  Is 
there a tipping point within a therapeutic area once biologics achieve a certain 
share of the product offerings or overall sales?  How do biologics respond when 
new small  molecules or smaller  biologics  such  as RNAi and peptides enter a 
market?   
B.  THE PRESENCE OF BIOLOGICS IS EXPANDING 
The  analyses  demonstrate  that  while  biologic  products  remain 
concentrated in a few therapeutic areas, their presence is expanding and can now 
be found at least in small numbers in nearly every large therapeutic class.  While 
it is too early to call it a trend, nearly half the new products approved in 2008 
were biologics.  
An examination of the drug development pipeline indicates that biologics 
have  the  potential  to  sustain  their  growth  as  a  larger  fraction  of  future  drug 
approvals.  We queried the IMS R&D Focus database which tracks both biologic 
and small  molecule therapeutic programs  in development.  Figure reveals that CHARACTERIZING  MARKETS  FOR  BIOPHARMACEUTICAL  INNOVATIONS: 
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biologics comprise over 40% of the late stage development pipeline tracked in 
IMS  R&D  Focus.    This  alone  suggests  the  potential  to  increase  the  biologics 
fraction of new product launches above their traditional level.  Others have found 
that  biologics  have  a  somewhat  higher  probability  of  overall  technical  and 
regulatory  success  once  they  reach  Phase  II  clinical  trials,  see    DiMasi  and 
Grabowski (2007).    If this pattern holds in the future, biologics could account for 
approximately half of future novel therapeutic approvals in the United States. 
Figure 12:  Biologics Percentage of Global Therapeutic Pipeline 
 
C.  OPPORTUNITY TO INCREASE NEW BIOLOGICS USE EARLIER? 
We  have  observed  substantial  differences  between  biologics  and  small 
molecules in their initial adoption and later stage continued growth.  The slower 
initial growth for biologics represents a relative lost opportunity to meet more 
patient needs if their adoption in the early quarters could be made similar to small 
molecules,  and  provided  it  were  medically  appropriate.    Potential  actions  that 
could be envisioned include more effectively identifying and educating physicians 
likely to be treating patients who would potentially benefit from the innovative 
biologic.    However,  we  also  recognize  that  biologics  typically  possess  patient 
inconvenience  properties  due  to  infusion  and  injections  that  may  limit  initial 
adoption and acceptance relative to that of comparable small molecules. CHARACTERIZING  MARKETS  FOR  BIOPHARMACEUTICAL  INNOVATIONS: 
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D.  REIMBURSEMENT APPROACHES DIFFER BOTH EARLY AND LATE 
IN THE PRODUCT CYCLE 
As  described  above,  Figure    displays  some  intriguingly  disparate 
commercial  behavior  between  small  molecules  and  biologics.    While  in  this 
research  we  present  no  evidence  explaining  the  differences,  we  suggest  the 
following hypotheses that future work and researchers might explore.  First, price 
increases may be inversely related to total sales of the product in later periods.  
Businesses and payers may manage not only to percentage changes but also to 
absolute amounts so that a small increase on a larger sales base for biologics may 
result  in approximately the same  incremental  new revenue (profit) as  a  larger 
increase on a lower revenue small molecule product.    This hypothesis may hold 
true particularly in the later periods when the mean inflation adjusted sales of 
biologics are nearly double those of small molecules.   Second, pricing may be 
related to firm type, data not included in our analysis.  Biologics may be more 
often marketed by smaller firms focused on research innovation with different 
attitudes and expectations regarding pricing than larger pharmaceutical firms that 
have more resources to devote to both research and business innovation.  Third, 
small  molecules  may  be  marketed  as  part  of  a  larger  portfolio  of  products 
enabling greater negotiation power, while biologics may be marketed by firms 
with smaller or narrower portfolios.  Fourth, since approaches to the pricing and 
reimbursement of retail-based prescription drugs generally differ from hospital or 
clinic-based prescription drugs, the likely skew of biologics toward the latter type 
may drive some of the distinctions observed here between small molecules and 
biologics.  In this context, we note that many biologics are provided as a medical 
rather than a drug benefit  in  health  insurance plans,  in contrast to most small 
molecules  that  are  administered  through  the  drug  benefit  component.    More 
detailed research with the current data and augmented with additional information 
could begin to address these hypotheses.   
E.  EXPERIENCES  VARY  CONSIDERABLY  AMONG  THERAPEUTIC 
CLASSES 
We  observed  substantial  heterogeneity  in  various  analyses  at  the 
therapeutic class level.  This suggests that therapeutic class dynamics may be as, 
if not more, important than therapeutic type in influencing commercial success.  
In some classes with large numbers of both biologics and small molecules such as 
oncology,  dynamics  may  play  out  at  an  individual  cancer  type  level  such  as 
breast,  colon,  lung,  prostate or  pancreatic  cancer.   The  emergence  of  targeted 
therapeutics  adds  a  further  dimension  of  potential  heterogeneity  among  the 
products.    Since  both  biologics  and  small  molecules  have  entered  this 
‗personalized medicine‘ space it is unclear to what extent product form proves 
influential in these markets.  However, we observe that many of the most noted CHARACTERIZING  MARKETS  FOR  BIOPHARMACEUTICAL  INNOVATIONS: 
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targeted therapeutics tend toward the biologic.  This suggests that the dominant 
factor in influencing commercial experience is not the scientific basis of a product 
but rather the dynamics of the therapeutic class in which it is competing and the 
basis of its competition. 
V.  SUMMARY, LIMITATIONS AND CONCLUSIONS 
In  this  research  project  we  have  constructed  and  analyzed  a  curated, 
annotated data set of every new NME product launched in the United States over 
the  eleven  year  period  from  1998  through  2008.    Analyses  of  that  data  have 
shown  that  the  commercial  experiences  of  biologics  and  small  molecules  are 
similar in many ways.  Many of the apparent mean differences, while suggestive, 
possess large standard deviations and so may narrow or even reverse in the future.  
Some,  however,  such  as  differences  in  orphan  drug  designation,  mean  sales 
growth and mean price changes suggest that material differences indeed exist in 
the commercial experiences of biologic and small molecule therapeutic products.   
Results  at  the  therapeutic  class  level  appeared  substantially  more 
heterogeneous for the subset of metrics which we examined.  Applying these total 
U.S. market results to any individual product or therapeutic area should therefore 
be done with caution. 
Other limitations of the work include that: 
  The post-1998 period examined – while a substantial period of more than a 
decade—excludes some of the most successful biologics (e.g., epoietin alfa, 
brand  name  Epogen)  and  small  molecules  (e.g.,  atorvastatin,  brand  name 
Lipitor)  on  the  market  during  the  period  and  continuing  to  current  time 
periods. 
  The sales data is not complete as the reported sales amounts do not include 
rebates  given  to  non-providers  (non-mail  order  PBMs,  HMOs,  etc.)  and 
perhaps other components of net sales; since prices are calculated as revenues 
divided by standard units, the pricing data should be viewed with caution. 
  The  post-1998  products  selected,  by  definition  include  many  recently 
launched products  and so do not portray the  full product life cycle.  This 
selection  approach  yields  declining  numbers  of  products  in  the  later  ‗time 
from launch‘ cohorts, generating small sample variability.   
  While 308 products in total were analyzed, many therapeutic class and later 
quarter cohorts may have relatively few observations which make analyses 
more challenging and conclusions more cautious. CHARACTERIZING  MARKETS  FOR  BIOPHARMACEUTICAL  INNOVATIONS: 
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  The  FDA  product  information  annotations  were  collected  via  a  targeted 
manual search process and so even with the care taken, it is possible that some 
items were not identified. 
  The  mean  growth  in  real  price  calculation  over  time  is  not  a  price  index 
similar to that published by the BLS, but is rather an unweighted arithmetic 
mean of annualized percentage price changes. 
  The data is for the U.S. market only and does not include the experiences of 
these  and  other  products  launched  in  other  world  regions  during  this  time 
period.    The  U.S.  market  structure  is  unique  in  the  world  and  so  direct 
extrapolation of these results to other regions may be inappropriate. 
  This analysis did not consider what fraction of revenues came from innovative 
therapies nor what fraction of all drug approvals and marketed therapeutics 
are novel, innovative, and targeted at unmet medical needs.  By definition, 
these analyses focused on NMEs which each bring a new active ingredient to 
the market.   
While the commercial experiences of biologics may be more similar to 
small  molecules  than  have  been  their  scientific,  manufacturing  and  regulatory 
paths,  the  market  dynamics  of  biologics  remain  unique.    With  biologics 
comprising  a  substantial,  and  likely  growing,  part  of  the  branded  market  the 
dynamics of ever more comingling of the two product types in more therapeutic 
areas by biopharmaceutical firms with ever more diverse biologic-small molecule 
product portfolios generates a fluid environment – but whether they mix to form a 
solution, suspension or oil and water separation, remains to be seen. 
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